%3Amax_bytes(150000)%3Astrip_icc()%2Ftal-amazon-outlet-deals-50-deals-tout-d9d17e2cd18c450ca95f92f3f90387c0.jpg&w=3840&q=100)
The 50 Best Amazon Outlet Deals for Travelers—Shop Samsonite Luggage, Brooks Shoes, and More Up to 74% Off
Right now, the outlet is offering massive deals on our favorite luggage brands, as well as travel clothes, comfortable shoes, and more. Keep reading for the 50 best deals, including Travelpro luggage, Brooks shoes, and more, up to 74 percent off.
Best Amazon Outlet Deals Overall
Amazon
Best Luggage and Travel Bag Deals
Amazon
Amazon's luggage outlet is full of our favorite brands. Shop a Delsey Paris luggage set, Samsonite carry-on, Travelpro softside luggage, and more. Plus, when you snag the now-$102 Travelers Club Hardside 4-piece Luggage Set, you'll get four luggage pieces for just $26 apiece. Don't forget to shop for secure crossbody bags and plane-ready backpacks, too. Prices start at just $27.
Samsonite Winfield 3 Dlx Hardside 20-inch Carry-on
Amazon
Travelers Club Hardside 4-piece Luggage Set
Amazon
Best Clothing Deals
Amazon
The overstock deals are heating up with these clothing pieces for men and women. Rebuild your travel wardrobe with the Anrabess Women's Palazzo Pants, Aimitag Eyelet Tank Top, and more. Plus, snag the best-selling Coofandy Men's Linen Shirt for just $30 today. Shop the best fashion deals from $10, ahead.
Anrabess Women's Palazzo Pants
Amazon
Coofandy Men's Linen Shirt
Amazon
Best Shoe Deals
Amazon
We'd recommend you snag these unbeatable shoe deals while they last. These impressive markdowns include podiatrist-approved pairs like the Crocs Unisex Adult Classic Clog, designer lookalikes such as the Cushionaire Women's Cork Footbed Sandals, and traveler-approved options, including the Brooks Women's Ghost 16 Running Shoe. Shop even more of Amazon's best shoes from just $18, below.
Brooks Women's Ghost 16 Running Shoe
Amazon
Reef Fanning Flip-flop
Amazon
Best Travel Accessory Deals
Amazon
Travel accessories are essential, but often unglamorous. With these practical items, you'll travel smoothly without needing to splurge. Shop a passport holder, travel pillow, and Apple AirTag holders, all under $10 and all highly rated. Plus, stay organized and pack more with the Bagsmart 6-set Compression Packing Cubes and Bagsmart Hanging Toiletry Bag. Shop the best travel accessories from $5, ahead.
Bagsmart 6-set Compression Packing Cubes
Amazon
Eachy Travel Makeup Bag
Amazon
Best Outdoor Gear Deals
Amazon
Whether your outdoor time means intensive camping trips or relaxing days on the beach, the Amazon Outlet has deals to make your adventures go smoothly. Plus, every home needs a pack of Cliganic Mosquito Repellent Bracelets, and they're selling quickly—over 100,000 shoppers bought them last month. Keep reading to shop for even more secret outdoor gear deals.
Cliganic Mosquito Repellent Bracelet 10-pack
Amazon
Cascade Mountain Folding Chair
Amazon
Love a great deal? Sign up for our T+L Recommends newsletter and we'll send you our favorite travel products each week.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Nebraska Dems hosting Kentucky Gov. Andy Beshear, possible 2028 presidential candidate
Kentucky Gov. Andy Beshear speaks during the Semafor World Economy Summit 2025 at Conrad Washington on April 23, 2025 in Washington, DC. () LINCOLN — Kentucky Gov. Andy Beshear is coming to Nebraska to speak to Democrats for the state party's top annual fundraising event in November. Beshear is a Democratic governor in a deeply red Republican state. He and other 2028 potential presidential hopefuls visited South Carolina in recent weeks, to test the water for their campaign messages. He was picked to lead the Democratic Governors Association into next year's midterm elections and has been touted as 'most popular Democratic governor in America.' Beshear was attorney general of Kentucky before becoming governor in 2019. His father was previously governor. National Democrats have been seeking answers as President Donald Trump made gains among working-class voters, including minority voters, last year. A trend of prominent Democratic figures making their way to the heartland has emerged, and some are crossing the Missouri River from traditionally first-in-the-nation Iowa into Nebraska. Independent U.S. Sen. Bernie Sanders launched his 'Fighting Oligarchy' nationwide tour in Omaha. Minnesota Gov. Tim Walz hosted a Democratic town hall earlier this year And Former Texas U.S. Rep. Beto O'Rourke is having a similar town hall in Omaha next month. The events with prominent Democratic figures appear aimed at energizing the Nebraska Democratic base for the midterms and come when two federal races could be competitive. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX Nebraska's 2nd Congressional District has drawn national attention as its single presidential race electoral vote has swung from Republicans to Democrats in recent years, most recently to former Vice President Kamala Harris in 2024. Nebraska could regain the national spotlight in 2026, with an open seat race in the state's 2nd District for the U.S. House and Dan Osborn's nonpartisan Senate bid against Republican U.S. Sen. Pete Ricketts. Both races could determine which party controls what parts of Congress. But Nebraska Democrats face an uphill battle in a state where Republicans outnumber Democrats about 2 to 1, Republicans have gained a legislative supermajority, and the party last held a congressional seat with former U.S. Rep. Brad Ashford in 2017. SUPPORT: YOU MAKE OUR WORK POSSIBLE
Yahoo
21 minutes ago
- Yahoo
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ('Palisade' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the 'Existing Warrants') to purchase up to an aggregate of 4,318,905 shares of common stock. The Existing Warrants had adjusted exercise prices of $1.40 and were issued by the Company on May 10, 2022; February 1, 2024; May 6, 2024; and December 13, 2024, with each exercise occurring at a reduced exercise price of $0.9047 per share. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this transaction. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to registration statements which were filed and declared effective by the Securities and Exchange Commission (the 'SEC'). The gross proceeds to the Company from the exercise of the Existing Warrants are expected to be approximately $3.9 million prior to deducting placement agent fees and estimated offering expenses. In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders will receive new unregistered warrants (the 'Replacement Warrants') to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the '1933 Act'). The Replacement Warrants will be exercisable, beginning on the effective date of stockholder approval, into an aggregate of up to 8,637,810 shares of common stock, at an exercise price of $0.9047 per share, and a term of exercise equal to five years from the date of shareholder approval. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The Replacement Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the 1933 Act and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Replacement Warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to Forward Looking Statements This communication contains 'forward-looking' statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: statements regarding the intended use of proceeds, the expected gross proceeds from the offering and the expected closing of the offering. These forward-looking statements are based upon the Company's current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company's forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company's clinical trials, the timing and success of preclinical studies and clinical trials conducted by the Company, the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company's product candidates in clinical trials focused on the same or different indications; and the Company's ability to secure additional financing to fund future operations and development of its product candidates. Additional risks and uncertainties can be found in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 24, 2025, as well as the Company's Quarterly Report on Form 10-Q, for the three-month period ended March 31, 2025, filed with the SEC on May 12, 2025. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. Investor Relations Contact JTC Team, LLCJenene Thomas 908-824-0775PALI@
Yahoo
21 minutes ago
- Yahoo
Tesla disappoints on earnings but wins on one major front
Tesla disappoints on earnings but wins on one major front originally appeared on TheStreet. Tesla didn't mention Bitcoin once in its second-quarter 2025 financial filing, even as investors and analysts scanned the company's balance sheet for any sign of movement in its crypto treasury. The silence isn't new. Tesla hasn't added or sold any Bitcoin for eight straight quarters, and the company's digital asset holdings remain unchanged at $184 million, according to the 10-Q form filed with the SEC on July 23. That's the same value it reported in the first quarter of 2024, with no impairment losses or gains noted this time either. Tesla had initially bought $1.5 billion worth of Bitcoin in early 2021. Since then, it's sold off the majority, with the last major sale happening in Q2 2022 when it offloaded roughly 75% of its BTC stash. Tesla holds 9,720 BTC as of its last disclosure. At today's Bitcoin price of $118,000, that stash is worth approximately $1.15 declines Beyond crypto, Tesla's earnings disappointed on several fronts. The company reported revenue of $22.5 billion — missing analyst estimates of $22.74 billion — and adjusted earnings per share of $0.40, below the expected $0.43. Automotive revenue fell 16% year-over-year, the second straight quarterly decline. In early July, Tesla had already reported a 14% drop in Q2 vehicle deliveries to 384,000 units. The stock is down roughly 18% this year, marking the worst performance among big tech names. By comparison, the Nasdaq Composite is up about 9% in 2025. Meanwhile, Tesla has delayed its affordable 'Model 2' EV, leaving the field open for rivals. Chinese EV makers are aggressively pushing cheaper, tech-laden vehicles that are eating into Tesla's global market share. Still holding the bag Despite the financial and political turbulence, Tesla appears to be holding firm on its crypto position—for now. But with mounting pressure from declining revenues and reputational hits, investors are watching closely for any future changes to the company's digital asset strategy. As of now, though, the Bitcoin line in Tesla's earnings reports remains quiet. No buys. No sells. Just HODLing. Tesla disappoints on earnings but wins on one major front first appeared on TheStreet on Jul 23, 2025 This story was originally reported by TheStreet on Jul 23, 2025, where it first appeared. Sign in to access your portfolio
